keyword
MENU ▼
Read by QxMD icon Read
search

Ulipristal acetate

keyword
https://www.readbyqxmd.com/read/28647614/inefficiency-of-ulipristal-acetate-on-uterus-leiomyomas-as-an-additional-sign-to-suspect-leiomyosarcoma
#1
Philippe Kadhel, Maïté Smail, Daphné Borja De Mozota
The unexpected diagnosis of a leiomyosarcoma from a surgical specimen of a presumed leiomyoma is rare, but with deleterious consequences, especially if morcellation techniques are used. There are currently no effective methods for such a preoperative diagnosis. Ulipristal acetate has demonstrated efficacy for the preoperative treatment of leiomyomas, but not for all patients. We report two cases of leiomyosarcomas in patients treated with ulipristal acetate for a presumed leiomyoma. We propose that ineffective ulipristal acetate treatment may indicate a population in which uterine leiomyosarcoma is more prevalent...
June 21, 2017: Journal of gynecology obstetrics and human reproduction
https://www.readbyqxmd.com/read/28631712/-the-molecular-mechanisms-and-morphological-manifestations-of-leiomyoma-reduction-induced-by-selective-progesterone-receptor-modulators
#2
T A Demura, Z V Revazova, E A Kogan, L V Adamyan
AIM: to investigate the molecular mechanisms and morphological substrate of reduced uterine leiomyoma in patients receiving the selective progesterone receptor modulator (SPRM) ulipristal acetate for 3 months, by estimating the immunohistochemical expression of the markers steroid receptor coactivator 1 (SRC-1), nuclear receptor corepressor 1 (NCoR-1), ER, PgR, Ki-67, p16, TGF-β, and VEGF in tumor tissue. SUBJECTS AND METHODS: The investigation enrolled 75 women with uterine leiomyoma, menorrhagias, and anemia...
2017: Arkhiv Patologii
https://www.readbyqxmd.com/read/28570936/a-uplc-ms-ms-method-for-the-quantitation-of-ulipristal-acetate-in-human-serum
#3
Renu Nandakumar, Piyapa Praditpan, Carolyn L Westhoff, Serge Cremers
The progesterone receptor modulator, Ulipristal acetate (UPA) has proven to be an effective emergency contraceptive. Conflicting data has been reported that suggests different efficacy of the drug in different populations, which may be explained by the systemic exposure to the drug. A UPLC-MS/MS method was developed and validated for the accurate and sensitive measurement of UPA in human serum to address this matter. UPA was extracted from human serum using liquid-liquid extraction with a combination of hexane and dichloromethane...
August 1, 2017: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
https://www.readbyqxmd.com/read/28567743/the-use-of-selective-progestin-receptor-modulators-sprm-and-more-specifically-ulipristal-acetate-in-the-practice-of-gynaecology
#4
REVIEW
Serge Rozenberg, Julie Praet, Eliza Pazzaglia, Christine Gilles, Yannick Manigart, Jean Vandromme
This review discusses the development of selective progestin receptor modulators (SPRM) for use in women's health and specifically the use of ulipristal acetate (UPA) as emergency contraception (EC) and as a treatment for symptomatic fibroids in women who want to preserve their fertility or avoid a hysterectomy. As an EC, UPA 30 mg should be recommended for women, within 102 h of unprotected intercourse. As a treatment of fibroids, UPA (5 mg daily dose) should be administered for periods of three months as a pre-surgical strategy, reducing bleeding and fibroid size and facilitating surgery...
June 1, 2017: Australian & New Zealand Journal of Obstetrics & Gynaecology
https://www.readbyqxmd.com/read/28498002/an-observation-study-of-the-clinical-evaluation-of-symptom-relief-and-side-effects-associated-with-taking-ulipristal-acetate-esmya-including-its-effect-on-pre-menstrual-syndrome
#5
Bee F Chen, Martin C Powell, Courtney O'Beirne
This was an observational study investigating the efficacy and side effects associated with ulipristal acetate (UPA), a progesterone receptor modulator, and the possible benefits to women who have co-existing pre-menstrual syndrome (PMS). 80 women returned a questionnaire on the bleeding, menstrual pain and side effects, and changes on PMS were recorded. 67 women (84%) showed improvement in their menses. 54 women (67%) became amenorrhoeic. Of those, 67% were within 10 days of commencing UPA. Menses returned in 33 amenorrhoeic women within 4 weeks of stopping UPA...
May 12, 2017: Journal of Obstetrics and Gynaecology: the Journal of the Institute of Obstetrics and Gynaecology
https://www.readbyqxmd.com/read/28485851/fibroid-vascularisation-as-a-predictor-for-uterine-fibroid-growth
#6
Margit Dueholm
There is a large variation in fibroid growth such that fibroids may grow at vastly different rates and conversely may spontaneously regress. The ability to predict the growth of fibroids could help clinicians decide, with their patients, the need for treatment. For example, asymptomatic women with fibroids detected incidentally may require follow up if these fibroids are predicted to have a high growth rate. In women of reproductive age, fast-growing fibroids located in a submucous or intramural position may subsequently impair fertility and so early surgical removal should be considered...
May 9, 2017: BJOG: An International Journal of Obstetrics and Gynaecology
https://www.readbyqxmd.com/read/28482329/endometrial-changes-during-ulipristal-acetate-use-a-systematic-review
#7
REVIEW
Inge De Milliano, Dominique Van Hattum, Johannes C F Ket, Judith A F Huirne, Wouter J K Hehenkamp
Ulipristal acetate is increasingly used for several clinical indications, like emergency contraception and pre-treatment of uterine fibroids. It has mixed progesterone agonist and antagonist effects in the myometrium and endometrium. Due to its progesterone antagonistic effect, an unopposed estrogen effect could occur which could cause (pre-)malignant lesions in the endometrium. Several studies have been performed to evaluate this possible increased risk for endometrial malignancies when using ulipristal acetate...
July 2017: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://www.readbyqxmd.com/read/28472576/ulipristal-acetate-an-update-for-australian-gps
#8
Danielle Mazza
BACKGROUND: In Australia, use and understanding of emergency contraception among women remains relatively low. This is despite the introduction of levonorgestrel emergency contraceptive pills (ECPs) more than a decade ago. In April 2016, a new ECP with the active ingredient ulipristal acetate became available in Australia. OBJECTIVE: The aims of this article are to increase understanding of the recently introduced ulipristal acetate ECP, including its safety profile, effi-cacy and special considerations; dispel common myths and misconceptions about emergency contraception; and to provide guidance on emergency contraceptive management in general practice, considering the recent advances...
2017: Australian Family Physician
https://www.readbyqxmd.com/read/28444736/selective-progesterone-receptor-modulators-sprms-for-uterine-fibroids
#9
REVIEW
Ally Murji, Lucy Whitaker, Tiffany L Chow, Mara L Sobel
BACKGROUND: Uterine fibroids are smooth muscle tumours arising from the uterus. These tumours, although benign, are commonly associated with abnormal uterine bleeding, bulk symptoms and reproductive dysfunction. The importance of progesterone in fibroid pathogenesis supports selective progesterone receptor modulators (SPRMs) as effective treatment. Both biochemical and clinical evidence suggests that SPRMs may reduce fibroid growth and ameliorate symptoms. SPRMs can cause unique histological changes to the endometrium that are not related to cancer, are not precancerous and have been found to be benign and reversible...
April 26, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28403922/place-of-ulipristal-acetate-in-the-management-of-uterine-fibroids-preoperative-treatment-or-sequential-treatment
#10
A-G Pourcelot, P Capmas, H Fernandez
Symptomatic uterine fibroids affect 25% of women of childbearing potential and are responsible for various symptoms, mainly menometrorrhagia, pelvic pain and infertility. No currently available medical treatment is able to eradicate fibroids. Two treatments are indicated preoperatively to reduce bleeding and decrease the size of fibroids: GnRH agonists and ulipristal acetate. Ulipristal acetate, a selective progesterone receptor modulator, exerts an antagonist effect on fibroid tissue, inducing apoptosis. It rapidly induces amenorrhoea (after an average of seven days of treatment) and reduces fibroid volume...
March 2017: Journal of gynecology obstetrics and human reproduction
https://www.readbyqxmd.com/read/28368774/pregnancy-outcomes-following-ulipristal-acetate-emergency-contraception-failure-a-report-of-five-cases
#11
Zeynep Ozturk, Emine Akgul
INTRODUCTION: The emergency contraceptive ulipristal acetate (UPA) 30 mg is increasingly used by women, but there is no published data on UPA exposure in pregnancy. CASE REPORT: Here we describe five cases of unintended pregnancies following the use of UPA for emergency contraception. Of five pregnant women exposed to UPA, one decided to terminate the pregnancy for personal reasons. Two of them experienced premature rupture of membranes and the babies were born large for gestational age (LGA)...
June 2017: Fetal and Pediatric Pathology
https://www.readbyqxmd.com/read/28351762/does-ulipristal-acetate-affect-surgical-experience-at-laparoscopic-myomectomy
#12
Lea Luketic, Lindsay Shirreff, Sari Kives, Grace Liu, Ramadan El Sugy, Nicholas Leyland, Meir Jonathon Solnik, Ally Murji
STUDY OBJECTIVE: To compare surgical experience of laparoscopic/robotic myomectomy in premenopausal patients pretreated with ulipristal acetate (UPA) with women not hormonally pretreated. DESIGN: A retrospective, multicenter cohort study of laparoscopic/robotic myomectomy procedure videos (Canadian Task Force Classification III). SETTING: Multiple university-affiliated tertiary care hospitals. PATIENTS: Fifty-five premenopausal women who underwent laparoscopic/robotic myomectomy for intramural myomas and were either pretreated with 3 months of UPA or had no hormonal pretreatment...
March 25, 2017: Journal of Minimally Invasive Gynecology
https://www.readbyqxmd.com/read/28292452/sometimes-you-do-get-a-second-chance-emergency-contraception-for-adolescents
#13
REVIEW
Ellen S Rome, Veronica Issac
Unplanned or unintended pregnancy remains a significant challenge for adolescents; many teens who plan ahead but opt not to choose long-acting reversible contraceptive methods have high failure rates with condom usage, oral contraceptives, and other less long-acting methods. Emergency contraception (EC) remains a necessity for those adolescents seeking a second chance to prevent the unintended consequences of unplanned sexual activity. At present, 5 postcoital methods remain available as EC globally: intrauterine devices, ulipristal acetate, a selective progesterone modulator, mifepristone; levonorgestrel, and ethinyl estradiol plus levonorgestrel or norgestrel (rarely used now that progestin only methods are more readily available)...
April 2017: Pediatric Clinics of North America
https://www.readbyqxmd.com/read/28267814/safety-after-extended-repeated-use-of-ulipristal-acetate-for-uterine-fibroids
#14
Bart C J M Fauser, Jacques Donnez, Philippe Bouchard, David H Barlow, Francisco Vázquez, Pablo Arriagada, Sven O Skouby, Santiago Palacios, Janusz Tomaszewski, Boguslaw Lemieszczuk, Alistair R W William
OBJECTIVE: To assess long term safety of extended repeated 3-month courses of ulipristal acetate (UPA) 10 mg/day, for up to 8 courses, with focus on endometrial and laboratory safety parameters. METHODS: This long-term, multi-center, open-label cohort, follow up study consisted of up to 8 consecutive 3-month courses of daily UPA 10 mg, each separated by a drug free period of 2 spontaneous menstrual bleeds. Sixty-four pre-menopausal women, with moderate to severe symptomatic uterine myoma(s) and heavy bleeding were enrolled and were studied for approximately 4 years...
2017: PloS One
https://www.readbyqxmd.com/read/28262240/heavy-menstrual-bleeding-an-update-on-management
#15
REVIEW
Joanna Davies, Rezan A Kadir
Heavy menstrual bleeding (HMB) is defined as excessive menstrual blood loss (MBL) >80 mL per cycle, that interferes with a woman's physical, emotional, social wellbeing and quality of life. Aetiology is due to underlying uterine pathologies, coagulopathy, ovulation dysfunction, or iatrogenic. Up to 20% of women with HMB will have an underlying inherited bleeding disorder (IBD). Assessment of HMB should entail a menstrual and gynaecological history and a bleeding score to distinguish those women who require additional haematological investigations...
March 2017: Thrombosis Research
https://www.readbyqxmd.com/read/28250723/ulipristal-acetate-before-high-complexity-endoscopic-hysteroscopic-laparoscopic-myomectomy-a-mini-review
#16
REVIEW
Włodzimierz Baranowski
Uterine myomas (fibromas, leiomyomas) are the most common tumours in women, and their clinical signs and symptoms are presented by 25-40% of patients with these benign tumours. According to current guidelines, the armamentarium for myoma management consists of: medical therapy (GnRH, SPRMs), non-surgical alternatives including uterine artery embolisation (UAE), vaginal temporary occlusion of uterine arteries using clamp-like device or MRgFUS technique, and surgical treatment (including minimally invasive techniques)...
December 2016: Przeglad Menopauzalny, Menopause Review
https://www.readbyqxmd.com/read/28238840/study-of-the-effect-of-ulipristal-acetate-on-human-sperm-ability-to-interact-with-tubal-tissue-and-cumulus-oocyte-complexes
#17
Carlos Zumoffen, Matías D Gómez-Elías, Adriana M Caille, Luis Bahamondes, Patricia S Cuasnicú, Débora J Cohen, María José Munuce
OBJECTIVE: Ulispristal acetate (UPA) is a selective progesterone receptor modulator widely used for emergency contraception (EC). The described main mechanism of action is by inhibiting or delaying ovulation; however, the postovulatory effects of the drug are still on debate. Therefore, the aim of this study was to determine whether UPA could interfere with human sperm fertilizing ability. STUDY DESIGN: Human motile spermatozoa were incubated under capacitating conditions with or without UPA, and then used to inseminate human tubal explants, mouse cumulus-oocyte complexes and zona-free hamster eggs...
June 2017: Contraception
https://www.readbyqxmd.com/read/28219738/ulipristal-acetate-administration-at-mid-cycle-changes-gene-expression-profiling-of-endometrial-biopsies-taken-during-the-receptive-period-of-the-human-menstrual-cycle
#18
Saúl Lira-Albarrán, Marta Durand, Marco F Larrea-Schiavon, Leticia González, David Barrera, Claudia Vega, Armando Gamboa-Domínguez, Claudia Rangel, Fernando Larrea
The aim of this study was to analyze the effects of mid-cycle administration of Ulipristal acetate (UPA) on gene expression in endometrial biopsies taken during the receptive phase of the cycle. Fourteen healthy menstruating women were studied during 14 control non-treated and 12 treated cycles with a single dose of 30 mg UPA when follicle diameter reached 20 mm. Ovulation in both treated and control cycles was confirmed by serial determinations of serum LH, progesterone and vaginal ultrasound. An endometrial biopsy at day LH+7, in each cycle, was taken for RNA microarray and qPCR analysis or prepared for histological and immunohistochemistry studies...
May 15, 2017: Molecular and Cellular Endocrinology
https://www.readbyqxmd.com/read/28217674/uterine-fibroid-shrinkage-after-short-term-use-of-selective-progesterone-receptor-modulator-or-gonadotropin-releasing-hormone-agonist
#19
Min Jin Lee, Bo Seong Yun, Seok Ju Seong, Mi-La Kim, Yong Wook Jung, Mi Kyoung Kim, Hyo Sook Bae, Da Hee Kim, Ji Young Hwang
OBJECTIVE: The aim of this study was to evaluate the effect of short-term use of selective progesterone receptor modulator (SPRM) or gonadotropin-releasing hormone (GnRH) agonist on uterine fibroid shrinkage among Korean women. METHODS: This retrospective study involved 101 women with symptomatic uterine fibroids who received ulipristal acetate (SPRM, n=51) and leuprolide acetate (GnRH agonist, n=50) for 3 months between November 2013 and February 2015. The fibroid volume was measured both before and after treatment using ultrasonography, computed tomography, and magnetic resonance imaging...
January 2017: Obstetrics & Gynecology Science
https://www.readbyqxmd.com/read/28185997/rationale-and-design-of-asteroid-2-a-randomized-placebo-and-active-comparator-controlled-study-to-assess-the-efficacy-and-safety-of-vilaprisan-in-patients-with-uterine-fibroids
#20
Christian Seitz, Žana Bumbuliene, Ana Rosa Costa, Oskari Heikinheimo, Andrea Heweker, Robert Hudeček, Yves Jacquemyn, Gian Benedetto Melis, Pooja Parashar, Tomasz Rechberger, Antonio Cano Sánchez, Bart van Aken, János Zatik, Kristina Gemzell-Danielsson
BACKGROUND: Uterine fibroids (UFs) may be treated with progesterone receptor modulators (PRMs), which have been shown to reduce heavy menstrual bleeding and the size of UFs. To date, one PRM (ulipristal acetate) has received regulatory approval for the treatment of UFs; therapy comprises intermittent treatment courses of up to 3months each, followed by a break to allow two menstruations to occur. We report the design of ASTEROID (Assess Safety and efficacy of vilaprisan in patients with uTERine fibrOIDs) 2, a phase 2 study examining the efficacy and safety of a novel PRM, vilaprisan, in women with UFs...
April 2017: Contemporary Clinical Trials
keyword
keyword
119605
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"